Clinical significance of survivin and caspase-3 expression in diffuse large B-cell lymphoma.
- Author:
Xiao-juan XIANG
1
;
You-jian HE
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; therapeutic use; Caspase 3; metabolism; Cyclophosphamide; administration & dosage; Doxorubicin; administration & dosage; Female; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; drug therapy; metabolism; pathology; Male; Microtubule-Associated Proteins; metabolism; Middle Aged; Neoplasm Proteins; metabolism; Neoplasm Staging; Prednisone; administration & dosage; Proportional Hazards Models; Recurrence; Remission Induction; Survival Rate; Vincristine; administration & dosage
- From: Chinese Journal of Oncology 2006;28(4):298-301
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of survivin and caspase-3, and its correlation with prognosis in diffuse large B-cell lymphoma (DLBCL).
METHODSFrom 1997 to 2000, 94 DLBCL patients were studied on the expression of survivin and caspase-3 detected by immunohistochemical stain. The relationship between the expression of surviving and caspase-3 and prognosis were analyzed by SPSS 10.0.
RESULTSThe positive expression rate of survivin and caspase-3 was 68.1% and 76.6%, respectively. The expression of survivin and caspase-3 were significantly correlated with the "international prognostic index" (IPI) (P < 0.05). Patients with positive expression of survivin and caspase-3 were found to have higer replase risk, and patients with positive survivin expression had poorer overall 5-year survival than those with negative expression (31.3% vs 64.0%, P < 0.05). Positive survivin expression was found to be an independent poor prognostic index for DLBCL by Cox regression model.
CONCLUSIONSurvivin and caspase-3 are useful in therapeutic and prognostic assessment. Poor prognostic patients can be screened out in the early treatment period using expression of survivin and caspase-3 combined with IPI, which may help to improve the outcome of diffuse large B-cell lymphoma.
